This is a company that has never made a profit. In fact, it’s never made any money at all. On top of that, analysts expect its per-share losses to double by the end of 2022. Assuming Adagio manages to generate some revenues next year — the market consensus is a minuscule $151 million — it’s already trading at almost 20 times those sales. Why? Because COVID is here to stay … and the search for a response is moving into new areas … quickly.
Vax In The Saddle Again I leave for a week of vacation, and I come back to … this? COVID-19 cases...Read More
May The Pfourth Be With You Great Ones, I don’t know if we officially have a winner in the...Read More
(4-minute read) The new crop of mRNA vaccines is a testament to scientific achievement in health care. They’re part of a much larger trend that we’ve been monitoring for a while. Here’s how to profit…
Newsletter Sign Up
The Banyan Edge is a daily look at what our top investment experts are buying, selling, and analyzing. Enter your email and start investing with an edge today.
CS Care Video
MEET OUR EXPERTS
Director of VIP Services
Director of Investment Research
CEO of Banyan Hill
Editor of Alpha Investor
Editor of One Trade and Precision Profits
Editor of Strategic Fortunes and three elite services
WHAT READERS ARE SAYING..
“My portfolio has grown from 275k to almost 900k with only investments made with Banyan Hill.”
- David G. (Member since 2018)
“I started with $215,000 in Nov. 2018, It is now over 800,000. So very happy with Banyan Hill Publishing.”
- Larry K.
"You have done once again!! You are reminding me of the GREAT Joe DiMaggio with your consistent hitting!! You knocked this one out of the park!"
- Keith S.